Forma Therapeutics Announces Appointment of Acclaimed Global Sickle Cell Disease Leader Ifeyinwa Osunkwo, MD, MPH, as Senior Vice President, Chief Patient Officer
30 November 2021 - 11:05PM
Business Wire
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a
clinical-stage biopharmaceutical company focused on rare
hematologic diseases and cancers, today announced the appointment
of Ifeyinwa (Ify) Osunkwo, MD, MPH, to the executive leadership
team as the company’s inaugural chief patient officer and senior
vice president. In this role, Dr. Osunkwo will be responsible for
realizing Forma’s vision to transform the lives of patients by
improving access and care through partnerships with global patient
and community stakeholders. She will join Forma in the first
quarter of 2022.
“This appointment of a chief patient officer boldly represents
our commitment to advancing both patient access and care as well as
potential innovative treatments. We are honored that Ify has chosen
to join Forma at this critical time in the growth of our
organization as a trusted patient-centered company,” said Frank
Lee, president and chief executive officer of Forma. “Ify
understands what it’s like to care for people living with sickle
cell disease firsthand because she’s dedicated her professional
life to it. Her role is crucial to our mission to transform patient
lives. We have no doubt the impact she will have at a global
level.”
Dr. Osunkwo is an internationally acclaimed expert in the
research, treatment and care delivery of sickle cell disease (SCD),
pediatric to adult care transition, and the management of chronic
pain. She has a passion for health equity and has focused her
research on identifying the comparative effectiveness of
interventions in eliminating health disparities in black and brown
populations. She has more than 25 years of experience in clinical
management, population health using the chronic disease management
model and health literacy. She is an accomplished clinician
educator adept at training clinical and non-clinical audiences and
is also a visionary leader in pragmatic program development and
implementation using quality improvement.
“I am thrilled to be able to continue building meaningful
partnerships with patient and community stakeholders in my role at
Forma,” said Dr. Osunkwo. “Improving the overall patient experience
in sickle cell disease has been my career passion; this is an
opportunity to really focus on the delivery of new treatments for
patients around the world. My vision is that everyone living with
sickle cell disease has access to basic care and disease
management. My hope is to amplify the impact I can have on the
community.”
Dr. Osunkwo is the Founder & Director of the Sickle Cell
Disease Enterprise at Levine Cancer Institute and a Professor of
Medicine and Pediatrics at Atrium Health - a vertically integrated
healthcare system serving 1400+ adults and 400+ children with
sickle cell disease in NC/SC/GA. Previously, she was the medical
director of the Comprehensive Sickle Cell Disease Program at
Children’s Healthcare of Atlanta @ Egleston and Assistant Professor
of Pediatrics at Emory University. She directed the Teen Scene
Transition Program that provided care coordination and education to
facilitate the smooth transition of young adults from pediatrics to
adult care. Dr. Osunkwo earned a medical degree from the University
of Nigeria College of Medical Sciences and Dentistry and an MPH
from Johns Hopkins University School of Hygiene and Public Health.
She received her pediatric residency training at the University of
Medicine and Dentistry of New Jersey and completed her fellowship
in pediatric hematology, oncology and bone marrow transplantation
at Columbia University College of Physicians and Surgeons. Dr.
Osunkwo is board certified in pediatric hematology oncology and has
led a robust research enterprise garnering over $15 million in
research funding and has served as principal investigator on
numerous clinical trials over the course of her career.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company
focused on the research, development and commercialization of novel
therapeutics to transform the lives of patients with rare
hematologic diseases and cancers. Our R&D engine combines deep
biology insight, chemistry expertise and clinical development
capabilities to create drug candidates with differentiated
mechanisms of action focused on indications with high unmet need.
Our work has generated a broad proprietary portfolio of programs
with the potential to provide profound patient benefit. For more
information, please visit www.FormaTherapeutics.com or follow us on
Twitter @FORMAInc and LinkedIn.
Forward-looking Statements
This press release may contain forward-looking statements and
information within the meaning of the Private Securities Litigation
Reform Act of 1995 and other federal securities laws. The use of
words such as “may,” “will,” “could,” “would,” “should,” “expects,”
“intends,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “projects,” “seeks,” “endeavors,” “potential,”
“continue,” “target” or the negative of such words or other similar
expressions can be used to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. The express or implied forward-looking
statements included in this press release are only predictions and
are subject to a number of risks, uncertainties and assumptions,
including, without limitation risks set forth under the caption
“Risk Factors” in Forma’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2021, as well as other risks detailed
in our subsequent filings with the Securities and Exchange
Commission. In light of these risks, uncertainties and assumptions,
the forward-looking events and circumstances discussed in this
press release may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. You should not rely upon
forward-looking statements as predictions of future events.
Although Forma believes that the expectations reflected in the
forward-looking statements are reasonable, it cannot guarantee that
the future results, levels of activity, performance or events and
circumstances reflected in the forward-looking statements will be
achieved or occur. Moreover, except as required by law, neither
Forma nor any other person assumes responsibility for the accuracy
and completeness of the forward-looking statements included in this
press release. Any forward-looking statement included in this press
release represents Forma’s views only as of the date on which it
was made. Forma undertakes no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211130005415/en/
Media: Adam Silverstein, +1 917-697-9313 Porter Novelli
adam.silverstein@porternovelli.com
Investor: Mario Corso, +1 781-366-5726 Forma Therapeutics
mcorso@formatherapeutics.com
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Forma Therapeutics (NASDAQ:FMTX)
Historical Stock Chart
From Aug 2023 to Aug 2024